ReviewNeuroscience bulletin2026
Pain-Affective Disorder Comorbidity in the Temporomandibular Disorders: From Mechanistic Insights to Clinical Management.
Review in Neuroscience bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Temporomandibular disorders (TMDs) comprise a spectrum of conditions affecting the temporomandibular joint, masticatory musculature, dental occlusion, and even multiple systemic structures. Epidemiological data indicate that approximately 40% of patients with TMDs experience comorbid affective disorders, creating complex diagnostic and therapeutic challenges, further resulting in suboptimal management. This review summarizes the comorbidity spectrum of TMDs, especially focusing on the bidirectional relationship between TMD-related pain and affective disorders, with the aims of (1) elucidating shared neurobiological mechanisms involving central sensitization, maladaptive neuroplasticity, and neuro-endocrine-immune dysregulation in TMDs; (2) analyzing the role of psychosocial factors in perpetuating this comorbidity; and (3) evaluating evidence-based treatment strategies that address both somatic and psychological symptoms. This review concludes by highlighting emerging new technologies with the potential for improved risk assessment and advocates for personalized treatment paradigms in this complex patient population. Future research directions should prioritize longitudinal studies examining the trajectories of comorbidity as well as testing emerging intervention approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.